参考文献
[1] Dai CF, Xie X, Yang YN, et al. Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population[J]. Lipids Health Dis, 2015,14:16. DOI: 10.1186/s12944‑015‑0007‑4.
[2] Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes‑based genome‑wide association meta‑analysis of coronary artery disease[J]. Nat Genet, 2015,47(10):1121‑1130. DOI: 10.1038/ng.3396.
[3] Wahrenberg A, Magnusson PK, Discacciati A, et al. Family history of coronary artery disease is associated with acute coronary syndrome in 28,188 chest pain patients[J]. Eur Heart J Acute Cardiovasc Care, 2020,9(7):741‑747. DOI: 10.1177/2048872619853521.
[4] Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)[J]. Circulation, 2018,138(14):1387‑1398. DOI: 10.1161/CIRCULATIONAHA.117.033200.
[5] Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia[J]. J Am Coll Cardiol, 2016,67(22):2578‑2589. DOI: 10.1016/j.jacc.2016.03.520.
[6] Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC‑Norfolk prospective population study[J]. Heart, 2010,96(24):1985‑1989. DOI: 10.1136/hrt.2010.210740.
[7] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics‑2017 update: a report from the American Heart Association[j]. Circulation,2017,135(10):e146‑e603. DOI: 10.1161/CIR.0000000000000485.
[8] Zheng YY, Wu TT, Gao Y, et al. A novel ABC score predicts mortality in non‑st‑segment elevation acute coronary syndrome patients who underwent percutaneous coronary intervention[J]. Thromb Haemost, 2021,121(3):297‑308. DOI: 10.1055/s‑0040‑1718411.
[9] Zheng YY, Wu TT, Liu ZQ, et al. Gut microbiome‑based diagnostic model to predict coronary artery disease[J]. J Agric Food Chem, 2020,68(11):3548‑3557. DOI: 10.1021/acs.jafc.0c00225.
[10] Lu X, Peloso GM, Liu DJ, et al. Exome chip meta‑analysis identifies novel loci and East Asian‑specific coding variants that contribute to lipid levels and coronary artery disease[J]. Nat Genet, 2017, 49(12):1722‑1730. DOI: 10.1038/ng3978.
[11] Lu X, Wang L, Chen S, et al. Genome‑wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease[J]. Nat Genet,2012,44(8):890‑894. DOI: 10.1038/ng.2337.
[12] Chen Z, Schunkert H. Genetics of coronary artery disease in the post‑GWAS era[J]. J Intern Med,2021,290(5):980‑992. DOI: 10.1111/joim.13362.
[13] Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease[J]. N Engl J Med, 2007,357(5):443‑453. DOI: 10.1056/NEJMoa072366.
[14] Dai CF, Xie X, Ma YT, et al. Haplotype analyses of CYP17A1 genetic polymorphisms and coronary artery disease in a Uygur population[J]. J Renin Angiotensin Aldosterone Syst,2015 ,16(2):389-398. DOI: 10.1177/1470320314565840.
[15] Wang DY, Wu TT, Zheng YY, et al. Nomogram developed with selenoprotein S (SelS) genetic variation and clinical characteristics predicting risk of coronary artery disease in a Chinese population[J]. Cardiovasc Diagn Ther, 2020,10(4):770‑777. DOI: 10.21037/cdt‑20‑296.
[16] Bentley AR, Sung YJ, Brown MR, et al. Multi‑ancestry genome‑wide gene‑smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids[J]. Nat Genet, 2019,51(4):636‑648. DOI: 10.1038/s41588‑019‑0378‑y.
[17] Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease[J]. N Engl J Med,2016,375(24):2349‑2358. DOI: 10.1056/NEJMoa1605086..
[18] Rhee EP, Ho JE, Chen MH, et al. A genome‑wide association study of the human metabolome in a community‑based cohort[J]. Cell Metab, 2013,18(1):130‑143. DOI: 10.1016/j.cmet.2013.06.013.
[19] Rhee EP, Yang Q, Yu B, et al. An exome array study of the plasma metabolome[J]. Nat Commun, 2016,7:12360. DOI: 10.1038/ncomms12360.
[20] Benson MD, Yang Q, Ngo D, et al. Genetic architecture of the cardiovascular risk proteome[J]. Circulation, 2018,137(11):1158‑1172. DOI: 10.1161/CIRCULATIONAHA. 117.029536.
[21] Emilsson V, Ilkov M, Lamb JR, et al. Co‑regulatory networks of human serum proteins link genetics to disease[J]. Science, 2018,361(6404):769‑773. DOI: 10.1126/science.aaq1327.
[22] Tandy‑Connor S, Guiltinan J, Krempely K, et al False‑positive results released by direct‑to‑consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care[J]. Genet Med,2018,20(12):1515‑1521. DOI: 10.1038/gim.2018.38.
[23] Krier JB, Kalia SS, Green RC. Genomic sequencing in clinical practice: applications, challenges, and opportunities[J]. Dialogues Clin Neurosci, 2016,18(3):299‑312. DOI: 10.31887/DCNS.2016.18.3/jkrier.
[24] Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation[J]. Nat Rev Genet, 2017,18(6):331‑344. DOI: 10.1038/nrg.2016.160.
[25] Lehrman MA, Schneider WJ, Südhof TC, et al. Mutation in LDL receptor: Alu‑Alu recombination deletes exons encoding transmembrane and cytoplasmic domains[J]. Science, 1985,227(4683):140‑146. DOI: 10.1126/science.3155573.
[26] Soria LF, Ludwig EH, Clarke HR, et al. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B‑100[J]. Proc Natl Acad Sci USA, 1989,86(2):587‑591. DOI: 10.1073/pnas.86.2.587.
[27] Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003,34(2):154‑156. DOI: 10.1038/ng1161.
[28] Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein[J]. Science, 2001,292(5520):1394‑1398. DOI: 10.1126/science.1060458.
[29] Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters[J]. Science, 2000,290(5497):1771‑1775. DOI: 10.1126/science.290.5497.1771.
[30] Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5‑lipoxygenase activating protein confers risk of myocardial infarction and stroke[J]. Nat Genet, 2004,36(3):233‑239. DOI: 10.1038/ng1311.
[31] Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease[J]. Science, 2003,302(5650):1578‑1581. DOI: 10.1126/science.1088477.
[32] Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel[J]. J Am Coll Cardiol,2018,72(6):662‑680. DOI: 10.1016/j.jacc.2018.05.044.
[33] Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody[J]. Circ Cardiovasc Genet, 2015,8(6):823‑831. DOI: 10.1161/CIRCGENETICS.115.001129.
[34] Luirink IK, Wiegman A, Kusters DM, et al. 20‑year follow‑up of statins in children with familial hypercholesterolemia[J]. N Engl J Med,2019,381(16):1547‑1556. DOI: 10.1056/NEJMoa1816454.
[35] Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial[J]. Int J Cardiol, 2013,168(4):3736‑3740. DOI: 10.1016/j.ijcard.2013.06.014.
[36] Fox CS, Hall JL, Arnett DK, et al. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association[J]. Circulation,2015,12,131(19):1715‑1736. DOI: 10.1161/CIR.0000000000000211.
[37] Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics[J]. J Intern Med,2013,273(1):6‑30. DOI: 10.1111/j.1365‑2796.2012.02592.x.
[38] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019,73(24):e285‑e350. DOI: 10.1016/j.jacc.2018.11.003.
[39] Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association[J]. J Clin Lipidol, 2022,16(5):e77‑e95. DOI: 10.1016/j.jacl.2022.08.007.
[40] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111‑188. DOI: 10.1093/eurheartj/ehz455.
[41] Assimes TL, Salfati EL, Del Gobbo LC. Leveraging information from genetic risk scores of coronary atherosclerosis[J]. Curr Opin Lipidol, 2017,28(2):104‑112. DOI: 10.1097/MOL.0000000000000400.
[42] Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart disease[J]. Eur Heart J, 2016,37(43):3267‑3278. DOI: 10.1093/eurheartj/ehw450.
[43] Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention[J]. J Am Coll Cardiol, 2018,72(16):1883‑1893. DOI: 10.1016/j.jacc.2018.07.079.
[44] Khera AV, Chaffin M, Aragam KG, et al. Genome‑wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations[J]. Nat Genet, 2018,50(9):1219‑1224. DOI: 10.1038/s41588‑018‑0183‑z.
[45] Lu X, Liu Z, Cui Q, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large‑scale prospective Chinese cohort study[J]. Eur Heart J,2022,43(18):1702‑1711. DOI: 10.1093/eurheartj/ehac093.
[46] Iribarren C, Lu M, Jorgenson E, et al. Clinical utility of multimarker genetic risk scores for prediction of incident coronary heart disease: a cohort study among over 51 000 individuals of European ancestry[J]. Circ Cardiovasc Genet, 2016,9(6):531‑540. DOI: 10.1161/CIRCGENETICS.116.001522.
[47] Wünnemann F, Sin Lo K, Langford‑Avelar A, et al. Validation of genome‑wide polygenic risk scores for coronary artery disease in french canadians[J]. Circ Genom Precis Med, 2019,12(6):e002481. DOI: 10.1161/CIRCGEN.119.002481.
[48] Mosley JD, Gupta DK, Tan J, et al. Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease[J]. JAMA, 2020,323(7):627‑635. DOI: 10.1001/jama.2019.21782.
[49] Elliott J, Bodinier B, Bond TA, et al. Predictive accuracy of a polygenic risk score‑enhanced prediction model vs a clinical risk score for coronary artery disease[J]. JAMA, 2020,323(7):636‑645. DOI: 10.1001/jama.2019.22241.
[50] Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in diverse human populations[J]. Nat Commun, 2019,10(1):3328. DOI: 10.1038/s41467‑019‑11112‑0.
[51] Wang M, Menon R, Mishra S, et al. Validation of a genome‑wide polygenic score for coronary artery disease in South Asians[J]. J Am Coll Cardiol, 2020,76(6):703‑714. DOI: 10.1016/j.jacc.2020.06.024.
[52] Cui Q, Liu Z, Li J, et al. Impact of cardiovascular health and genetic risk on coronary artery disease in Chinese adults[J]. Heart,2023,109(10):756‑762. DOI: 10.1136/heartjnl‑2022‑321657.
[53] Li J, Liu M, Liu F, et al. Age and genetic risk score and rates of blood lipid changes in China[J]. JAMA Netw Open,2023,6(3):e235565. DOI: 10.1001/jamanetworkopen.2023.5565.
[54] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华预防医学杂志, 2019, 53(1): 13-35. DOI: 10.3760/cma.j.issn.0253-9624.2019.01.004.
[55] Kullo IJ, Jouni H, Austin EE, et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low‑density lipoprotein cholesterol levels (the MI‑GENES Clinical Trial)[J]. Circulation,2016,133(12):1181‑1188. DOI: 10.1161/CIRCULATIONAHA.115.020109.
[56] Marston NA, Kamanu FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER Trial[J]. Circulation,2020,141(8):616‑623. DOI: 10.1161/CIRCULATIONAHA.119.043805.
[57] Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials[J]. Lancet, 2015,385(9984):2264‑2271. DOI: 10.1016/S0140‑6736(14)61730‑X.
[58] Ahmad F, McNally EM, Ackerman MJ, et al. Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association[J]. Circ Genom Precis Med,2019,12(6):e000054.DOI: 10.1161/HCG.0000000000000054.